English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background The mutation L76V is selected under lopinavir (LPV)-, amprenavir (APV)and darunavir (DRV)-containing regimens with increasing prevalence. L76V decreases susceptibility to LPV and APV, and increases susceptibility to SQV and ATV. However, little is known about the clinical implication of this mutation in the response to PI-containing regimens in patients with strongly limited therapy options.

L76V – clinically relevant resensitization of the protease inhibitors (PIs) saquinavir (SQV) and atazanavir (ATV)